Strattera and Sexual Side Effects
Strattera (atomoxetine) causes sexual dysfunction primarily in adult males, with erectile dysfunction occurring in 8-21% and ejaculation disorders in 2-6% of patients, while sexual side effects in women and adolescents are minimal and comparable to placebo. 1
Sexual Side Effects Profile
Adult Males (Highest Risk)
The FDA label clearly documents that adult male patients experience significantly higher rates of sexual dysfunction compared to placebo 1:
- Erectile dysfunction: 8.0% (atomoxetine) vs 1.9% (placebo) in extensive metabolizers; 21% in poor metabolizers vs 9% in extensive metabolizers
- Ejaculation disorder: 2.8% vs 1.1% (placebo); 6% in poor metabolizers
- Decreased libido: 4.6% vs 3.0% (placebo)
- Orgasm abnormalities: reported but less common
Critical caveat: The FDA label explicitly states that sexual dysfunction is likely underreported because patients and physicians are reluctant to discuss these issues 1. Research confirms this, with actual rates potentially much higher 2.
Women and Adolescent Males
Sexual side effects in these populations are clinically similar to placebo and not a major concern 2, 3.
CYP2D6 Poor Metabolizers
This genetic subgroup (approximately 7% of the population) experiences dramatically higher rates of sexual dysfunction—erectile dysfunction occurs in 21% of poor metabolizers versus 9% in extensive metabolizers 1. Poor metabolizers have significantly higher plasma levels and longer half-lives, leading to increased adverse effects 4.
Time Course of Sexual Side Effects
Onset: Sexual dysfunction typically appears within 2-3 weeks of starting atomoxetine 5, 2:
- Genitourinary symptoms (urinary hesitation, dysuria): within first 2 weeks
- Erectile and ejaculation issues: during weeks 2-3 of dosing
Resolution: After discontinuation, sexual side effects resolve with median times of 3-8 weeks depending on the specific symptom 5, 2. Some sexual side effects have a "lingering course" with resolution times up to 53 days 5.
Evaluation and Management Algorithm
1. Pre-Treatment Assessment
- Screen for baseline sexual function before initiating atomoxetine
- Consider CYP2D6 genotyping if available, especially in patients concerned about sexual side effects 4, 1
- Document cardiovascular risk factors (sexual dysfunction shares risk factors with cardiovascular disease) 6
2. During Treatment Monitoring
Physicians must routinely and explicitly inquire about sexual side effects at each visit 1, 7. Do not wait for spontaneous reporting—patients rarely volunteer this information.
Specifically ask about:
- Erectile function
- Ejaculation difficulties
- Libido changes
- Urinary hesitation or retention (often accompanies sexual dysfunction) 1, 7
3. Management When Sexual Dysfunction Occurs
Option A: Dose Reduction
- Lower the atomoxetine dose while maintaining therapeutic benefit
- Sexual side effects appear dose-dependent 2, 3
Option B: Drug Holiday
- Not practical for ADHD medication requiring consistent daily dosing
Option C: Switch Medications
- Discontinue atomoxetine if sexual dysfunction is intolerable
- Consider alternative ADHD medications:
- Expect resolution within 3-8 weeks after discontinuation 5
Option D: Watchful Waiting
- Some patients find sexual side effects tolerable
- Weigh ADHD symptom control against quality of life impact
4. Special Considerations
Drug Interactions: CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine) increase atomoxetine levels 6-8 fold, dramatically increasing sexual dysfunction risk 1. Avoid this combination or reduce atomoxetine dose by 50% if CYP2D6 inhibitors are necessary.
Genitourinary symptoms: Urinary hesitation, retention, and dysuria frequently co-occur with sexual dysfunction 1, 7. These typically appear within 2 days of starting atomoxetine and resolve within 2 days of discontinuation 7.
Comparison to antidepressants: While guidelines note that psychotropic drugs generally affect sexual function 6, atomoxetine's sexual side effect profile in adult males is clinically significant and requires the same vigilant monitoring as SSRIs 9.
Key Clinical Pitfalls
- Failing to proactively ask about sexual side effects—they will not be spontaneously reported
- Ignoring CYP2D6 status—poor metabolizers have 2-3 times higher risk
- Missing drug interactions with CYP2D6 inhibitors that dramatically worsen sexual dysfunction
- Assuming sexual side effects resolve quickly—median resolution is 3-8 weeks, not days
- Not documenting baseline sexual function—makes it impossible to determine if dysfunction is drug-related